Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PACS vs SGRY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PACS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

PACS Overall Winner 6-Pillar Tally: PACS 4 – 2 SGRY Matrix Metrics: PACS 8 – 2 SGRY

As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PACS vs SGRY
PACS NYSE Head-to-Head Winner
PACS Group, Inc.
Services-Skilled Nursing Care Facilities
$43.67
+1.49% 1D
Market Cap $6.8B
TTM Revenue $5.71B
Forward P/E 15.3x
Beta / 30D Vol 0.78β · 51% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 35.0 Fund 48.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.2 · SMA20: $48.01 · SMA50: $45.43
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56

6-Pillar Scorecard Institutional Category Breakdown (PACS 4 – 2 SGRY)

Columns: Metric · PACS · SGRY
1. Valuation Multiples PACS
Forward P/E 15.3x N/M
Trailing P/E 26.2x N/M
PEG Ratio 1.22x 1.66x
EV / Revenue 1.8x 1.9x
2. Growth & Scale PACS
Revenue Growth (YoY) +11.5% -0.8%
Earnings Growth (YoY) +15.6% +0.0%
TTM Revenue (USD) $5.71B $3.36B
Market Cap $6.8B $3.5B
3. Profitability & Quality SGRY
Gross Margin 17.8% 22.2%
Operating Margin 7.4% 13.2%
Net Profit Margin 4.9% -2.6%
Return on Equity (ROE) 26.5% 2.1%
4. Balance Sheet & Cash Flow SGRY
Cash Generation (TTM) $8.2M $203M
Cash Flow Margin 0.1% 6.0%
Net Cash / Leverage $3.29B Net Debt (2.81x D/E) $2.96B Net Debt (1.99x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PACS
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 46.1% (11th %ile) 62.1% (34th %ile)
Put/Call OI Skew 0.52x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat PACS
OpEx & R&D Intensity 10.4% of Rev ($593M) 9.0% of Rev ($302M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PACS (8) vs SGRY (2)
Institutional Metric PACS SGRY Criterion Row Edge
Market Capitalization
Scale
$6.8B $3.5B Larger Scale PACS
Trailing P/E Ratio
Valuation
26.2x N/M Lower Multiple PACS
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple PACS
Revenue Growth (YoY)
Growth
+11.5% -0.8% Higher Growth PACS
Operating Margin (TTM)
Profitability
7.4% 13.2% Higher Margin SGRY
Net Profit Margin
Profitability
4.9% -2.6% Higher Margin PACS
Return on Equity (ROE)
Capital Efficiency
26.5% 2.1% Higher ROE PACS
52-Week Range Position
Momentum
79% ($14–$52) 97% ($11–$27) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
0.78β · 51% Vol 0.87β · 166% Vol Lower Realized Risk PACS
Unified Institutional Score
Composite Signal
46.8 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite PACS
Trailing 12M Revenue (USD)
Operating Scale
$5.71B $3.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.8% 22.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.22x PEG · 1.8x EV/Rev 1.66x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.2M ($3.29B Net Debt (2.81x D/E)) $203M ($2.96B Net Debt (1.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +76.49 pp
PACS: -8.06% · SGRY: +68.43%
3M Horizon SGRY +93.28 pp
PACS: -1.31% · SGRY: +91.97%
6M Horizon SGRY +84.17 pp
PACS: +15.68% · SGRY: +99.85%
1Y Horizon PACS +89.02 pp
PACS: +159.48% · SGRY: +70.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PACS Revenue SGRY Revenue PACS Op. Margin SGRY Op. Margin Margin Leader
FY2018 N/A $1.77B N/A 4.4% SGRY
FY2019 N/A $1.83B N/A 12.9% SGRY
FY2020 N/A $1.86B N/A 9.8% SGRY
FY2021 N/A $2.23B N/A 13.6% SGRY
FY2022 $2.40B $2.54B 9.6% 13.6% SGRY
FY2023 $3.11B $2.74B 6.7% 12.0% SGRY
FY2024 $4.09B $3.11B 3.0% 11.2% SGRY
FY2025 $5.29B $3.31B 5.9% 11.8% SGRY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PACS CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 46.1%
IV Percentile 11th %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PACS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $49.00 · IV 47.5%

PACS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($4,900)

Compare $4,900 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 47.5% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $50 / $55 Bull Call Spread

Buy 1x $50C · Sell 1x $55C · 32d

Net Entry $103 Debit
T+5d @ +5% Move +$65 (+63%)
Max Risk / Buffer $103 Capped
5d Edge & Liquidity 1.1x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $45 / $40 Bull Put Spread

Sell 1x $45P · Buy 1x $40P · 32d

Net Entry $104 Credit
Max Credit / Yield +$104 (+26.3% RoM)
Max Risk / Buffer -10.3% Cushion ($396 Mgn)
5d Edge & Liquidity 73% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $45P / $50-$55C Seagull

Sell 1x $45P · Buy 1x $50/$55C · 32d

Net Entry $47 Credit
T+5d @ +5% Move +$146 (+21.3% RoM)
Max Risk / Buffer -8.2% Put Cushion ($683 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PACS Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $6.8B market capitalization and 7.4% operating margin.
OpEx & R&D Reinvestment 10.4% of Rev ($593M)
90D Engineering Disclosures 0 Published
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published

Investor FAQ PACS vs SGRY Key Questions & Quantitative Answers

As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Technically, PACS sits in a Neutral phase (RSI 39.2, CONSOLIDATION options structure) and SGRY sits in a Markup phase (RSI 84.4, SURGE options structure).

PACS leads the Growth & Scale pillar: PACS posts +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACS cumulative revenue shifted +120.4% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, PACS deploys 10.4% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.

PACS screens cheaper on headline valuation multiples. PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACS (26.5% ROE) versus SGRY (2.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.